Skip to main content

Table 2 Etiologies and lifetime tobacco consumption in past and current smokers

From: Tobacco and end stage renal disease: a multicenter, cross-sectional study in Argentinian Northern Patagonia

Etiology of end-stage renal disease

Lifetime tobacco consumption (% and 95 % CI)

Total (number and %)

Light <5 pack/years

Medium 5–15 pack/years

High 16–25 pack/years

Very high >25 pack/years

Diabetes

19.6 (16.6-22.6)

24.7 (22.1-27.2)

15.4 (13–17.8)

24.7 (21.9-27.6)

79 (21.5)

Glomerulonephritis

23.4 (16.5-30.2)

19.8 (19.2-20.3)

12.8 (10.4-15.3)

13.5 (8.5-18.5)

70 (19.1)

Nephrosclerosis

15.2 (8.2-22.2

16 (13.2-18.9)

28.2 (24.9-31.6)

27 (20.4-33.5)

72 (19.6)

Unknown

23.4 (20.8-26)

19.8 (18.1-21.4)

28.2 (25.7-30.7)

18 (14.6-21.4)

80 (21.8)

Obstructiveuropathy

6.3 (5.6-7)

3.7 (1.2-6.2)

2.6 (0.9-4.2)

12.4 (7.4-17.3)

25 (6.8)

Others

12 (10.7-13.4)

16 (12.1-20)

12.8 (12.2-13.5)

4.5 (1.45-10.4)

41 (11.2)

Total (number and %)

158 (43)

81 (22)

39 (11)

89 (24)

367 (100)

  1. Lifetime tobacco consumption (LTC) was calculated in pack-years. The change observed in etiology distribution achieved statistical significance (χ 2 = 42.23; p < 0.0001). The diagnosis of nephrosclerosis increased from 15.2 % and 16 % in patients with light and medium LTC to 28.2 % and 27 % in patients with high and very high LTC (bold text)